Bradley A. McGregor, MD, director of Clinical Research for the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, discusses the advancements in treating metastatic renal cell ...

Jacob Sands, MD, discusses the benefits of the arrival of Dato-DXd into the EGFR-positive non–small cell lung cancer treatment landscape and the next steps in research for this agent.

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.